SEE Program Boosts Medication Adherence, Reduces Distress in Michigan Patients

For individuals navigating the challenges of glaucoma, a chronic eye condition that can lead to irreversible vision loss, maintaining consistent medication adherence is crucial. Recent findings from a study conducted in Michigan suggest that a personalized health coaching program, known as SEE (Support, Educate, Empower), significantly improves patients’ ability to follow their prescribed medication regimens and reduces associated distress.

The study, published in PubMed, enrolled 235 adults diagnosed with glaucoma who were already using eye drops to manage their condition. Participants self-reported adherence rates of 85% or lower before entering the trial, indicating a clear need for support. The SEE program, a six-month intervention, combined motivational interviewing techniques with personalized education and automated medication reminders.

Understanding the SEE Intervention

The SEE program isn’t a one-size-fits-all approach. It’s built around the idea that understanding a patient’s individual barriers to medication adherence is the first step toward overcoming them. The program includes three in-person sessions with a non-physician counselor, four follow-up phone calls, and tailored educational materials delivered through multimedia formats. Crucially, the program too incorporates automated reminders to help patients stay on track with their eye drop schedules. This multifaceted approach distinguishes it from standard written education, which often proves insufficient for sustained behavioral change.

The researchers recruited participants from two major health systems in Michigan: the University of Michigan (UM) and Henry Ford Health System (HFHS) between April 2021 and December 2023. This broad recruitment base strengthens the generalizability of the findings. Participants were randomly assigned to either the SEE intervention group or a control group that received the usual care – three mailings containing standard glaucoma education materials.

Measuring Adherence and Distress

The primary outcome of the study was medication adherence, which was electronically monitored using the AdhereTech device. This technology provides an objective measure of whether patients are taking their medication as prescribed, eliminating the potential for recall bias inherent in self-reported adherence data. Adherence was calculated as the percentage of doses taken on time, compared to those prescribed over the six-month study period.

Beyond adherence, the study also assessed glaucoma-related distress, recognizing that the emotional burden of managing a chronic condition can significantly impact quality of life. Changes in distress levels were measured using validated questionnaires, providing a holistic view of the program’s impact.

What the Results Showed

The results demonstrated a clear benefit for those participating in the SEE program. Although mean self-reported adherence at the start of the study was 63.9%, participants in the intervention group showed improved adherence compared to the control group. Medscape reports that patients in the SEE program were more likely to adhere to their medication regimen and experienced less distress related to their condition. The study did not specify the exact magnitude of the improvement in adherence rates, but the finding is nonetheless significant given the challenges of managing glaucoma long-term.

The Importance of Addressing Non-Adherence

Glaucoma is a leading cause of irreversible blindness in the United States, and medication non-adherence is a major contributing factor to vision loss. Even with effective treatments available, if patients don’t take their medication consistently, the disease can progress, leading to irreversible damage to the optic nerve. This highlights the critical need for interventions that address the behavioral and emotional aspects of managing chronic conditions like glaucoma.

The SEE program’s success suggests that a personalized, supportive approach can be highly effective in improving adherence and reducing distress. This is particularly crucial for a condition like glaucoma, where consistent treatment is essential for preserving vision. AJMC highlights the program’s employ of personalized multimedia education, medication reminders, and motivational interviewing-based coaching as key components of its success.

Limitations and Future Directions

While the study provides promising results, it’s important to acknowledge its limitations. The study was conducted in a single geographic region (Michigan) and involved participants from two specific health systems. This raises questions about whether the findings would be generalizable to other populations and healthcare settings. The study also did not include a long-term follow-up period, so it’s unclear whether the benefits of the SEE program are sustained over time.

Further research is needed to confirm these findings in larger, more diverse populations and to assess the long-term impact of the intervention. Future studies could also explore the cost-effectiveness of the SEE program and identify the specific components that are most effective in improving adherence and reducing distress.

What This Means for Patients and Providers

The findings from this study underscore the importance of addressing medication adherence as a key component of glaucoma care. For patients, this means actively engaging in conversations with their healthcare providers about any challenges they are facing with their medication regimen. For providers, it means considering the use of interventions like the SEE program to support patients in adhering to their treatment plans.

The National Eye Institute provides comprehensive information about glaucoma, including risk factors, symptoms, and treatment options: https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/glaucoma.

Looking Ahead: Program Expansion and Integration

The success of the SEE program in Michigan is prompting discussions about potential expansion to other regions and integration into routine glaucoma care. Health systems are evaluating the feasibility of training non-physician counselors to deliver the SEE intervention and incorporating automated medication reminders into existing electronic health record systems. Ongoing monitoring of adherence rates and patient-reported outcomes will be crucial to assess the program’s effectiveness and identify areas for improvement.